← Eichor
Study identifier: NCT06953843 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

Condition: NSCLC Stage IV Without EGFR/ALK Mutation  ·  Sponsor: Xinqiao Hospital of Chongqing

PhasePhase 2
Planned participants366
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and low-toxic treatment strategy for non-small cell lung cancer (NSCLC) with multiple metastases. The main objective is to explore and compare the control rates of abscopal lesions in NSCLC patients with multiple metastases when different radiotherapy fractionation patterns are combined with Benmelstobart.

This description comes directly from the study's public registry record.

Talk to the study team

Jianguo Sun, MD  ·  86-13983155736  ·  sunjg09@aliyun.com

Always discuss trial participation with your own doctor first.

Locations (1)

the second affiliated hospital of Army medical universityChongqing, Chongqing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06953843